The findings could significantly improve treatment approaches for millions affected by AMD, as halting drusen accumulation may prevent vision loss.

The study was published on October 2, 2024, in the journal Developmental Cell, offering hope for millions affected by AMD.

Currently, there are no treatments available that can stop the progression of AMD, which is most prevalent in individuals over the age of 50.

Existing treatments for AMD have limited efficacy and can cause significant side effects.

Drusen, lipid-protein-rich deposits, accumulate in the retinal pigment epithelium (RPE) and are early indicators of AMD.

The study, led by Dr. Ruchira Singh from the University of Rochester, utilized human stem cells to model AMD, overcoming limitations of previous animal model studies.

Targeting inflammation pathways linked to TIMP3 has shown promise in reducing drusen formation in stem cell models of AMD.

Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the United States, affecting up to 15 million Americans.

Researchers have identified a key protein involved in the early stages of AMD by examining genes related to AMD and macular dystrophies.

The research team includes co-authors from multiple institutions and was supported by the National Eye Institute and other organizations.

The research was supported by various organizations, including the National Eye Institute and the ForeBatten Foundation.

The study aims to find new therapeutic targets to potentially halt AMD progression.